1. Medtech Insight
  3. >>R&D

Angle Reels In Positive Clinical Results In Ovarian Cancer Study

 
• By Catherine Longworth

Liquid biopsy company Angle plc, has reported positive results for its first large-scale study in Europe and the US using its Parsortix system to detect ovarian cancer. The study evaluated 400 patients for the detection of ovarian cancer in women with a high-risk pelvic mass.

UK-based liquid biopsy company Angle plc has reported positive results from its first large-scale study using the Parsortix system to detect ovarian cancer. The company completed two independent studies, at the University of Texas MD Anderson Cancer Center and at the University of Vienna in Europe.

The two studies evaluated more than 400 patients for detection of ovarian cancer and triaging patients with abnormal pelvic mass....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Liquid Biopsy Startup Mursla Bio Launches AI Precision Medicine Platform

 
• By Natasha Barrow

The new AI Precision Medicine platform supports the company’s flagship product, EvoLiver, which received US FDA breakthrough device designation in April.

Veterinary Heart Health Goes High-Tech: Eko And Boehringer Use AI To Spot Heart Murmurs In Dogs

 
• By Marion Webb

Eko hopes its new partnership with Boehringer Ingelheim to develop algorithms for accurately detecting heart murmurs in dogs will pave the way for more collaborations with medical and pharmaceutical companies to advance early detection in humans as well as animals.

Prix Galien Spotlights Mental Health ‘Renaissance’ But Systemic Hurdles Persist

 
• By Natasha Barrow

Experts at the Prix Galien UK Forum discussed the future of mental health innovation, emphasizing the important roles of digital solutions, diagnostic biomarkers and community involvement.